ES2124257T3 - Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores. - Google Patents

Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores.

Info

Publication number
ES2124257T3
ES2124257T3 ES92910345T ES92910345T ES2124257T3 ES 2124257 T3 ES2124257 T3 ES 2124257T3 ES 92910345 T ES92910345 T ES 92910345T ES 92910345 T ES92910345 T ES 92910345T ES 2124257 T3 ES2124257 T3 ES 2124257T3
Authority
ES
Spain
Prior art keywords
composition
equipment
tumor activity
tumors
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910345T
Other languages
English (en)
Other versions
ES2124257T4 (es
Inventor
Tetsuhiko Shirasaka
Masakazu Fukushima
Hideyuki Ohshimo
Yuji Shimamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of ES2124257T3 publication Critical patent/ES2124257T3/es
Application granted granted Critical
Publication of ES2124257T4 publication Critical patent/ES2124257T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA POTENCIAR LA ACTIVIDAD ANTITUMORAL DEL TEGAFUR Y REDUCIR LOS SUS EFECTOS ADVERSOS, LA COMPOSICION COMPRENDE UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) EN LA QUE X REPRESENTA HALOGENO O CIANO Y ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ASI COMO UN METODO Y UN EQUIPO PARA EL USO DEL COMPUESTO, ASIMISMO SE PRESENTA UNA COMPOSICION PARA CURAR TUMORES QUE COMPRENDE TEGAFUR, UN COMPUESTO REPRESENTADO POR LA FORMULA (I) Y UN ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; ASI COMO UN METODO Y UN EQUIPO PARA LOS MISMOS.
ES92910345T 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores. Expired - Lifetime ES2124257T4 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP121247/91 1991-05-27
JP12124791 1991-05-27
PCT/JP1992/000656 WO1992021345A1 (en) 1991-05-27 1992-05-22 Composition, method and kit for potentiating antitumor activity and for curing tumor

Publications (2)

Publication Number Publication Date
ES2124257T3 true ES2124257T3 (es) 1999-02-01
ES2124257T4 ES2124257T4 (es) 2012-03-23

Family

ID=14806544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910345T Expired - Lifetime ES2124257T4 (es) 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores.

Country Status (14)

Country Link
US (1) US5525603A (es)
EP (1) EP0543015B1 (es)
JP (1) JP2614164B2 (es)
KR (1) KR0148589B1 (es)
AT (1) ATE173165T1 (es)
AU (1) AU654555B2 (es)
CA (1) CA2087540C (es)
DE (2) DE69227571T2 (es)
DK (1) DK0543015T3 (es)
ES (1) ES2124257T4 (es)
HU (1) HU211987A9 (es)
LU (1) LU91852I2 (es)
TW (1) TW209833B (es)
WO (1) WO1992021345A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
JP2002255828A (ja) * 2001-02-28 2002-09-11 Ajinomoto Co Inc 抗腫瘍剤
RU2346686C2 (ru) * 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
CN101357134A (zh) * 2003-03-14 2009-02-04 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
SI1750703T1 (sl) * 2004-04-29 2012-02-29 Taiho Pharmaceutical Co Ltd Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
KR100844477B1 (ko) 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
CN101912399B (zh) * 2005-04-01 2012-05-23 大鹏药品工业株式会社 放射线治疗增强剂
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
CN101921227B (zh) * 2007-04-03 2012-09-05 南京工业大学 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
WO2010104035A1 (ja) 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
PL2415870T3 (pl) 2009-03-31 2017-01-31 Delta-Fly Pharma, Inc. Cząsteczka RNAi dla syntazy tymidylanowej i jej zastosowanie
US8992947B2 (en) 2009-04-22 2015-03-31 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of chemotherapy on renal cell cancer
AU2010248710A1 (en) 2009-05-12 2011-12-01 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
WO2011052554A1 (ja) 2009-10-27 2011-05-05 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 新規５－フルオロウラシル誘導体
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
JPWO2012105486A1 (ja) 2011-01-31 2014-07-03 大鵬薬品工業株式会社 １日１回隔日投与を特徴とするテガフール含有組成物
EP2711704B1 (en) 2011-05-16 2017-06-28 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
AU2012259803B2 (en) * 2011-05-25 2016-03-17 Taiho Pharmaceutical Co., Ltd. Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN103159673B (zh) * 2011-12-12 2015-02-04 山东新时代药业有限公司 一种制备吉美嘧啶的精制方法
US20150110864A1 (en) 2012-03-16 2015-04-23 Taiho Pharmaceutical Co., Ltd. Novel antitumor agent comprising combination of three agents
TW201400810A (zh) * 2012-06-01 2014-01-01 大鵬藥品工業股份有限公司 對胃癌患者選擇化學療法之方法
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
JPS562913A (en) * 1979-06-21 1981-01-13 Ono Pharmaceut Co Ltd Antitumor agent
JPS5646867A (en) * 1979-09-25 1981-04-28 Ono Pharmaceut Co Ltd Pyridone derivative, its preparation and antineoplasmic agent
DK175432B1 (da) * 1984-10-30 2004-10-18 Otsuka Pharma Co Ltd Middel til forögelse af anticancervirkningen af anticancerforbindelser
JPS62155215A (ja) * 1984-11-30 1987-07-10 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
US5116600A (en) * 1989-01-05 1992-05-26 Otsuka Pharmaceutical Co., Ltd. Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
JPH0578249A (ja) * 1991-09-20 1993-03-30 Taiho Yakuhin Kogyo Kk ５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

Also Published As

Publication number Publication date
KR0148589B1 (ko) 1998-11-02
WO1992021345A1 (en) 1992-12-10
TW209833B (es) 1993-07-21
LU91852I2 (fr) 2011-10-03
EP0543015A4 (en) 1994-06-01
EP0543015A1 (en) 1993-05-26
CA2087540A1 (en) 1992-11-28
US5525603A (en) 1996-06-11
JP2614164B2 (ja) 1997-05-28
CA2087540C (en) 1999-01-19
DE122011100040I1 (de) 2011-11-24
AU654555B2 (en) 1994-11-10
DE69227571D1 (de) 1998-12-17
EP0543015B1 (en) 1998-11-11
AU1791292A (en) 1993-01-08
ATE173165T1 (de) 1998-11-15
ES2124257T4 (es) 2012-03-23
DE69227571T2 (de) 1999-04-29
DK0543015T3 (da) 1999-07-26
DE122011100040I2 (de) 2012-08-09
HU211987A9 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
ES2137932T3 (es) Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2093694T3 (es) Nuevos derivados de dihidro-isoquinoleina.
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
DK339184D0 (da) Imidazoliumforbindelser, mellemprodukter hertil og fremgangsmaade til deres anvendelse
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
FI865233A0 (fi) Pyrazolinderivat, deras framstaellning och anvaendning som medel med insekticid och akaricid verkan.
ES8704170A1 (es) Un procedimiento para preparar derivados de guanina
ES8302025A1 (es) Procedimiento para la preparacion de 10-alquinil esteroides
ES8504183A1 (es) Un nuevo procedimiento para la preparacion de nuevos cromanos y cromenos.
ES2009723A4 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
DE69015736D1 (de) 7-Keto- und 7-Hydroxy-androsta-3,5-dien-3-carbonsäure Derivate.
ES2055037T3 (es) Derivados de 4-amino-3-acil-quinolina y su uso como inhibidores de la secrecion de acido gastrico.
ES2045044T3 (es) Derivados de sulfonamidolfenilo y agentes terapeuticos y preventivos de la arritmia que contienen los mismos.
ES8402297A1 (es) Un procedimiento de preparacion de derivados de imidazo-(1,2-)piridina.
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
GR78806B (es)
ATE30583T1 (de) Vitamin-d3-derivate.
ES2062758T3 (es) Nuevos analogos de vitamina d.
ES2091249T3 (es) Analogos de iludina utilizables como agentes antitumorales.
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
NO932722L (no) Salter av et 4-amino-3acyl-kinolinderivat og deres anvendelse som inhibatorer for gastrisk syresekresjon
ES8502435A1 (es) Un metodo para preparar 2(1h)-piridinonas
MX9300008A (es) Nucleosidos terapeuticos.
ES8504182A1 (es) Procedimiento para preparar nuevos derivados de piperidina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 543015

Country of ref document: ES